Department of Dermatology, International University of Health and Welfare, Chiba, Japan.
Department of Pathology, International University of Health and Welfare, Chiba, Japan.
J Dermatol. 2024 Jan;51(1):120-124. doi: 10.1111/1346-8138.16981. Epub 2023 Sep 27.
A case of cytoplasmic anaplastic lymphoma kinase (ALK)-positive anaplastic large cell lymphoma (ALCL) initially involving the skin in a 44-year-old Japanese female is reported. The patient had a hemorrhagic erythematous tumor on the right thigh without any systemic symptoms. Pathology showed diffuse infiltration of CD30-positive anaplastic large cells positive for epithelial membrane antigen and cytoplasmic ALK. The right inguinal lymph node showed infiltration of tumor cells in the marginal sinus. Only 2 weeks after radiation therapy, the patient developed multiple subcutaneous nodules and lung involvement. Even after subsequent multichemotherapy sessions, cutaneous recurrence occurred. Literature review of cytoplasmic ALK-positive ALCL initially involving in the skin revealed that skin lesions were mostly seen in the extremities and that half of the cases developed extracutaneous lesions. Radiation and chemotherapy were effective for most cases. Inverse RT-PCR identified a tumor necrosis factor receptor-associated factor (TRAF)1-ALK fusion in our case. Most reported cases with this translocation experienced repeated changes in chemotherapy, suggesting poorer prognosis. Although ALK-positive ALCL generally responds well to chemotherapy, the presence of a TRAF1-ALK fusion may suggest resistance to treatment. Detection of fusion partners of ALK is important for predicting clinical courses and deciding treatment options.
本文报道了一例 44 岁日本女性初发皮肤累及的细胞质间变性淋巴瘤激酶(ALK)阳性间变大细胞淋巴瘤(ALCL)。患者右大腿有一处出血性红斑性肿瘤,无任何全身症状。病理表现为弥漫性浸润 CD30 阳性的上皮膜抗原阳性和细胞质 ALK 阳性的间变大细胞。右腹股沟淋巴结边缘窦内可见肿瘤细胞浸润。仅在放射治疗后 2 周,患者即出现多发皮下结节和肺部受累。即使随后进行了多次化疗,皮肤仍复发。对初发皮肤累及的细胞质 ALK 阳性 ALCL 的文献复习显示,皮肤病变多发生于四肢,半数病例发生皮肤外病变。放射和化疗对大多数病例有效。我们的病例通过反转录聚合酶链反应(RT-PCR)鉴定出肿瘤坏死因子受体相关因子(TRAF)1-ALK 融合。大多数报道的具有这种易位的病例经历了化疗的反复改变,提示预后较差。尽管 ALK 阳性 ALCL 通常对化疗反应良好,但 TRAF1-ALK 融合的存在可能提示治疗耐药。检测 ALK 的融合伙伴对于预测临床过程和决定治疗方案很重要。